Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARLANEC: Tarlatamab vs Chemotherapy in Pre-treated Advanced Neuroendocrine Carcinomas
NCT06937905Phase 3Recruiting
- Sponsor
- IFCT
- Start
- Feb 2026
- Primary completion
- Feb 2029
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in neuroendocrine carcinoma (NEC) comparing Standard of care chemotherapy with Tarlatamab (2 arms). Primary endpoint: Overall Survival at 4 years. Started Feb 2026; status: recruiting.
02
Drugs
tarlatamab
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT06937905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06937905.